Malady Kyle 4

What Happened

• Kyle Malady, EVP and Group CEO — VZ Business, received a grant of 144.943 phantom shares (derivative award) on 2026-07-01. The filing reports an attributable value of $11.99 per unit, totaling about $1,738. This was an award/grant (not a purchase or sale) and is a form of deferred compensation rather than an open-market trade.

Key Details

• Transaction date & terms: 2026-07-01 — Award of 144.943 phantom stock units at $11.99 each (total ≈ $1,738).
• Transaction type: A (award/grant) — derivative (phantom stock), cash-settled.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each phantom share is an economic equivalent of a common share and is settled in cash under the deferred compensation plan; payable upon events set by the reporting person. F2 — includes phantom stock acquired through dividend reinvestment.
• Filing date: Form 4 filed 2026-07-06 (accession 0001760581-26-000036); the filing does not indicate a late-report flag.

Context

• Phantom stock awards are a deferred compensation vehicle that mimic share value but are typically settled in cash, so they do not increase share count outstanding. Such awards are routine for executive compensation and do not, by themselves, signal a buy or sell decision.